Oncotarget

Research Papers:

Anti-β2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy

Mingjun Zhang, Jin He, Zhiqiang Liu, Yong Lu, Yuhuan Zheng, Haiyan Li, Jingda Xu, Huan Liu, Jianfei Qian, Robert Z. Orlowski, Larry W. Kwak, Qing Yi and Jing Yang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:8567-8578. https://doi.org/10.18632/oncotarget.3251

Metrics: PDF 1337 views  |   HTML 1342 views  |   ?  


Abstract

Mingjun Zhang1,2, Jin He1, Zhiqiang Liu1, Yong Lu1,2, Yuhuan Zheng1,2, Haiyan Li1,2, Jingda Xu1, Huan Liu1, Jianfei Qian1,2, Robert Z. Orlowski1, Larry W. Kwak1, Qing Yi1,2, Jing Yang1,3

1Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

2Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA

3Cancer Research Institute and Cancer Hospital, Guangzhou Medical University, Guangzhou, China

Correspondence to:

Jing Yang, e-mail: jiyang@mdanderson.org

Qing Yi, e-mail: yiq@ccf.org

Keywords: multiple myeloma, anti-β2M monoclonal antibody, bortezomib, autophagy, NF-κ p65

Received: November 17, 2014     Accepted: January 29, 2015     Published: March 31, 2015

ABSTRACT

Our previous studies showed that anti-β2M monoclonal antibodies (mAbs) have strong and direct apoptotic effects on multiple myeloma (MM) cells, suggesting that anti-β2M mAbs might be developed as a novel therapeutic agent. In this study, we investigated the anti-MM effects of combination treatment with anti-β2M mAbs and bortezomib (BTZ). Our results showed that anti-β2M mAbs enhanced BTZ-induced apoptosis of MM cell lines and primary MM cells. Combination treatment could also induce apoptosis of BTZ-resistant MM cells, and the enhanced effect depended on the surface expression of β2M on MM cells. BTZ up-regulated the expression of autophagy proteins, whereas combination with anti-β2M mAbs inhibited autophagy. Sequence analysis of the promoter region of beclin 1 identified 3 putative NF-κB-binding sites from –615 to –789 bp. BTZ treatment increased, whereas combination with anti-β2M mAbs reduced, NF-κB transcription activities in MM cells, and combination treatment inhibited NF-κB p65 binding to the beclin 1 promoter. Furthermore, anti-β2M mAbs and BTZ combination treatment had anti-MM activities in an established MM mouse model. Thus, our studies provide new insight and support for the clinical development of an anti-β2M mAb and BTZ combination treatment to overcome BTZ drug resistance and improve MM patient survival.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3251